Search the Newsreel

ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach

ImmunityBio (IBRX) is under investor scrutiny after receiving marketing authorization in the UAE for ANKTIVA, used for bladder cancer and lung cancer. While the stock has seen significant year-to-date gains, its current valuation reflects rich revenue multiples and ongoing losses. Analysts present mixed views, …

Bombay Super Hybrid Seeds Publishes Q1 FY27 Unaudited Results in Line with SEBI Norms

Bombay Super Hybrid Seeds Q1 Results: Net profit rises 16% YoY

Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next

ImmunityBio (IBRX) saw its stock rise by 6.6% following its Q2 2026 results and the expanded UAE marketing authorization for its immunotherapy ANKTIVA, now covering bladder and lung cancer in 34 countries. Despite increased revenue, the company reported wider net losses, highlighting the challenge …

Cybin (HELP) Names New CEO, Is The Stock Still Cheap?

Cybin (HELP) has appointed Michael Halstead as its new CEO, leading to significant short-term share price momentum with a 48.47% return over 7 days and 118.64% over 90 days, despite a long-term decline. A Simply Wall St. narrative suggests the stock is 69.1% undervalued …

Yuanbao Inc (YB) Stock News Today

This article provides current stock information for Yuanbao Inc (YB), including its latest stock price, market capitalization, and P/E TTM ratio. It notes that more news, earnings, and analyst ratings for Yuanbao Inc will be available soon. The page serves as a hub for …

Mainz Biomed N V Ord Shs (QUCY) Stock News Today

This page provides current stock news for Mainz Biomed N V Ord Shs (QUCY), including its stock price, market cap, and links to financial data, analyst ratings, and ownership information. As of the latest update, the stock was trading at $1.440, up 4.35%. The …

ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value

ImmunityBio (IBRX) has shown strong stock performance with a 321.9% gain over three years, driven by recent approvals for ANKTIVA. However, the stock appears overvalued based on its current Price-to-Sales (P/S) ratio of 46.8x, significantly higher than the biotech industry average. While there is …

Yuanbao Inc (YB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Yuanbao Inc (YB) has an earnings forecast score of 6.00, placing it 85th out of 115 in the Insurance industry. Based on one analyst, the current rating for YB is "Hold" with a target price of $17.90, representing a potential upside of 30.94%. The …

Cyber Media (India) Ltd is Rated Sell

Cybin Inc (CN:HELP) Rallies 4.62%: rebranded psychedelic-medicine developer is trading briskly after a new CEO and an ahead-of-schedule Phase 3 enrollment,

Cybin Inc, now operating as Helus Pharma (CN:HELP), saw its stock rally 4.62% to C$15.40 with high relative volume, following a new CEO appointment on August 3, 2026, and the early completion of Phase 3 trial enrollment on July 21, 2026. While no specific …

Bombay Super Hybrid Seeds Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Bombay Super Hybrid Seeds Q1 Net Profit At 143M Rupees; Revenue Reaches 1.8B Rupees

Bombay Super Hybrid Seeds standalone net profit rises 16.54% in the June 2026 quarter

ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise …

The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses

In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, while reporting second-quarter 2026 revenue of US$51.24 million and a net loss of US$230.38 million. The …

Maybulk Berhad Q2 2026 Financial Results: Revenue, Profit, Segment Analysis, and Land Disposal Updates

Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale?

Helus Pharma appointed Michael Halstead as CEO, a move that could significantly influence Cybin's strategic direction. Halstead's extensive experience in commercialization and M&A in the biopharma sector may reshape how Cybin approaches growth, partnerships, and capital allocation, especially as it moves towards potential commercialization …

Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPS

ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake

ImmunityBio, Inc. (IBRX) is majority-controlled by Patrick Soon-Shiong and affiliated entities, who beneficially own 64.8% of the common stock, totaling 745,518,285 shares. This ownership is distributed among several entities, including Cambridge Equities, Nant Capital, California Capital Equity, and NantWorks. The report is based on …

Rallybio Corp 2Q 2026: Revenue $0 Net income $43.67M, EPS $7.53— 10-Q Summary

Rallybio Corp reported Q2 2026 results with $0 revenue and a net income of $43.67 million, or $7.53 diluted EPS, a significant increase from a net loss in the prior year. This financial improvement was driven by strategic transactions, including a $50 million termination …

Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

FMR LLC reports 15% Rallybio Corp (RLYB) stake, including 5% fund holding

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 15.0% in Rallybio Corp (RLYB), totaling 794,720 shares of common stock as of June 30, 2026. This stake includes a 5.0% holding by the Fidelity Growth Company Commingled Pool, amounting to 265,132 …

Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed?

Cybin's stock (HELP) surged 33.1% after appointing Michael Halstead, a veteran from Helus Pharma, as its new CEO. Halstead brings 25 years of biopharma experience, including significant roles in acquisitions and commercialization of psychiatric drugs, which could transform Cybin's late-stage development. While this appointment …

Cybin (Helus Pharma, HELP) Leaps 14% Ahead of Pivotal Depression Trial Data

Helus Pharma (formerly Cybin, stock symbol HELP) saw its shares jump 14.02% ahead of crucial Phase 3 trial data for its lead depression drug, HLP003, expected in Q4 2026. The company recently appointed a new CEO and completed trial enrollment ahead of schedule, with …

Maybulk Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Rallybio (NASDAQ: RLYB) wins $50M fee, plans merger with Avenzo

Rallybio Corporation reported a significant swing to profitability in Q2 2026, driven by a $50 million termination fee from its canceled merger with Candid Therapeutics, resulting in a net income of $43.7 million. The company now plans to merge with Avenzo Therapeutics, a clinical-stage …

Century Plyboards (India) Ltd (BOM:532548) (Q1 2027) Earnings Call Highlights: Record Revenue ... By GuruFocus

Moneyboxx Finance Ltd is Rated Strong Sell

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

Helus Pharma (Nasdaq: HELP) has appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO, effective immediately. This strategic move comes months before the company's pivotal Phase 3 data readout for HLP003, a novel serotonergic agonist for Major Depressive Disorder (MDD) which has received …

Cybin continues rally following CEO appointment, up another 13% (HELP:NASDAQ)

Shares of Cybin Inc. (HELP), a clinical-stage biopharmaceutical company focused on psychedelic-based treatments, rose over 13% on Wednesday. This continued a rally initiated by the announcement of Michael Halstead's appointment as CEO. The article also briefly discusses potential impacts of the CEO change on …

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio IBRX reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period's loss of 10 cents. Total revenues …

HYBE Co., Ltd. (KRX:352820) 주가가 181,000원일 때 이 종목을 살펴볼 필요가 있을까요?

Century Plyboards posts 57.3% profit surge in Q1FY27; earnings call audio released

Should You Investigate HYBE Co., Ltd. (KRX:352820) At ₩181,000?

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) reported a Q2 loss of $0.08 per share, surpassing the Zacks Consensus Estimate of a $0.09 loss and showing an 11.11% earnings surprise. The company also beat revenue estimates, posting $51.24 million against an estimated $48.45 million. ImmunityBio's stock has seen a …